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Abstract: Current treatments for Crohn’s disease are aimed at suppressing excessive immune 
activation in the bowel walls. However, alternative strategies can be drawn. These involve 
the augmentation of the innate immune response, in the hypothesis that patients affected with 
Crohn’s disease are characterized by a relative immunodeﬁ  ciency, with failure of the defensive 
barrier to luminal microbes and microbial products, resulting in a chronic inﬂ  ammatory process 
sustained by T-cells. Alternatively, therapy could act by enhancing the number or the activity 
of subpopulations of T regulatory cells, able to reduce T-cell activation. Colony-stimulating 
factors are substances that could be efﬁ  cacious in these settings. In fact, besides in vitro 
and animal studies, some human studies have been conducted in recent years with both 
granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor, 
the results of which are reported here.
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Introduction
Crohn’s disease (CD) is a chronic inﬂ  ammatory, granulomatous disorder occurring 
throughout the gastrointestinal tract. The cause remains unknown, although various 
genetic (Satsangi et al 2003) and environmental (Ekbom and Montgomery 2004) 
factors have been postulated.
While the fundamental etiology of CD remains unknown, the prevailing hypothesis 
focuses on an excessive immune reaction as the underlying problem. Defects in the 
interaction between innate and adaptive immune response may play a crucial role in 
the development of inﬂ  ammation in inﬂ  ammatory bowel disease (IBD).
Furthermore, a variety of T-cell defects have been observed in IBD. These include 
an excess of Th1 and Th17-type responses with excess of interleukin (IL)-12/IL-23 and 
interferon (IFN) γ/IL-17 production in CD, and defects in T-cell programmed cell death 
(apoptosis) (Brown and Mayer 2007). Furthermore, defects in regulatory T-cell function 
have been hypothesized in IBD. All of this modiﬁ  es immune tolerance and predisposes 
to intestinal inﬂ  ammation. In IBD there is a breakdown in mucosal tolerance.
The aim of this review is to describe the results of experimental and clinical 
trials of treatments with granulocyte colony-stimulating factor (G-CSF) and 
granulocyte-macrophage colony-stimulating factor (GM-CSF), directed at augmenting 
the intestinal innate immune defense rather than suppressing a secondary inﬂ  ammatory 
response (Korzenik and Dieckgraefe 2000; Podolsky 2002; Wilk and Viney 2002) and 
possibly to improve T regulatory cell activity which may be effective in CD.
Medical treatment of IBD
The aims of medical treatment in IBD are: modiﬁ  cation of the microbial environment to 
remove the antigenic drive; modiﬁ  cation of the immune response, including inhibition Therapeutics and Clinical Risk Management 2008:4(5) 928
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of the expression, synthesis or function of proinﬂ  ammatory 
cytokines; increasing the activity of anti-inflammatory 
cytokines; inhibiting the proliferation of inﬂ  ammatory cells 
and their recruitment into the intestine.
In facts, current treatments for CD are aimed to 
suppress the immune system to restore health. Established 
medical strategies for the treatment of CD include the 
use of immunosuppressive agents such as corticosteroids, 
azathioprine or 6-mercaptopurine, methotrexate.
Recent therapeutic innovations, such as anti-TNF-α 
antibodies like infliximab and adalimumab, have been 
designed to be more selective, interfering with speciﬁ  c 
elements of the inﬂ  ammatory cascade.
Several other so called “biologic therapies” are currently 
under study, among which are monoclonal antibodies 
directed against several cytokines and receptors like 
IL-12/IL-23, IFNγ, IL-6R, CD3, or blocking leucocyte 
adhesion related molecules (α4-integrin, α4β7-integrin, 
ICAM-1). Some proposed biologic therapy are aimed to 
stimulate anti-inﬂ  ammatory pathways (rhuIL-10, rhuIL-11, 
CTLA4-Ig, CD40L) or to inhibit signal transduction through 
MAP-kinase.
Colony-stimulating factors
Growth factors have recently emerged as potential tools for 
the modulation of intestinal inﬂ  ammation and repair. At 
least 30 different growth factors are relevant for the main-
tenance of gut mucosal integrity, including transforming 
growth factor beta (TGF-beta), insulin-like growth factor 
(IGF), keratinocyte-like growth factor (KGF), epidermal 
growth factor (EGF), growth hormone (GH), and the colony-
stimulating factors (GM-CSF, G-CSF, and macrophage 
colony-stimulating factor [M-CSF]) (Dignass and Sturm 
2001; Playford and Ghosh 2005). Each of these regulatory 
peptide families plays an important role in the modulation 
of cellular proliferation, differentiation, angiogenesis, and 
inﬂ  ammation; moreover, they serve an important function as 
messengers between the intestinal mucosa, enteric nervous 
system, and immune system. Although the hematopoietic 
tissues are the predominant site of action for these pep-
tides, they are produced throughout the body, including the 
intestine, and are also produced by constituents of the lamina 
propria (primarily macrophages or monocytes) (Dignass 
and Sturm 2001).
The greatest body of evidence supporting the use of 
colony-stimulating factors in intestinal inﬂ  ammation comes 
from studies conducted with GM-CSF and G-CSF in patients 
with CD.
In this framework, two possible pathogenetic mechanisms 
support the therapeutic use of agents like growth factors in 
IBD: the “innate immunodeﬁ  ciency” hypothesis and the 
“T regulatory cell defect” hypothesis.
Innate immunodeﬁ  ciency in IBD
The innate immune network represents the ﬁ  st line response 
to microbial infections, and has a crucial relevance in the 
gut, where the lining mucosa has to face the enormous load 
of the intestinal microbiota. Several cell types respond to 
bacteria in a way independent from prior antigen exposure: 
these are cells coming from the bloodstream (neutrophils, 
monocytes) or resident in the gut (dendritic and Paneth 
cells, intestinal epithelial cells with their range of secreted 
antimicrobic peptides). The hypothesis that has recently 
been focused is that CD patients may possess a diminished 
initial inﬂ  ammatory response (Korzenik and Dieckgraefe 
2000). Speciﬁ  cally, CD may result from defective function-
ing of intestinal innate immune defense. Breakdown of this 
defensive barrier may permit persistent exposure of lamina 
propria cells to luminal microbes and microbial products, 
resulting in an aberrant, chronic inflammatory process 
mediated by T-cells.
Defects of several components of the innate immune 
network have been described in CD, which may drive the 
response towards an excessive inﬂ  ammation sustained by 
the adaptive immune response network. Polymorphisms have 
been described in CD patients for some toll-like receptors 
(TLR) expressed on monocytes/macrophages, dendritic 
and epithelial cells and for NOD molecules, both implied 
in recognizing pathogen-associated molecular patterns. The 
role of the innate immune system in the pathogenesis of IBD 
has been recently emphasized after the identiﬁ  cation of the 
NOD2/CARD15 gene, expressed in macrophages and Paneth 
cells as a disease susceptibility gene (Hugot et al 2001; Ogura 
et al 2001). CARD-15 variants in CD are associated with 
modiﬁ  cations in nuclear factor-κB activation, leading to an 
inappropriate immune response to the muramyl dipeptide 
component of bacteria. This, and other unknown mechanisms, 
may lead to activation of the adaptive immune response. The 
interpretation of these genetic defects, however, is not fully 
understood. NOD2 mutations have been interpreted both 
as being of “gain of function” type, leading to uncontrolled 
inﬂ  ammation, as well as of “loss of function” type, in that 
case allowing the penetration of microbes in the gut mucosa, 
ie, lowering the threshold of defence from infection.
Interestingly, Crohn’s-like intestinal disease has been 
identiﬁ  ed in patients with genetic disease, such as chronic Therapeutics and Clinical Risk Management 2008:4(5) 929
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granulomatous disease (GCD), glycogen storage disease 
1b (GSD-1b), and cyclic neutropenia, in which a variety of 
qualitative or quantitative neutrophil deﬁ  ciencies or other 
defects in innate immunity have been well characterized, 
have a therapeutic beneﬁ  t of recombinant human granulo-
cyte colony-stimulating factor (rhuG-CSF) and recombinant 
human granulocyte/macrophage colony-stimulating factor 
(rhuGM-CSF). Several cases of GSD-1b patients with an IBD 
indistinguishable from idiopathic CD have been described. 
These patients have severe neutropenia and impairment 
of neutrophils function. Yamaguchi and colleagues (2001) 
reported a case of GSD-1b with IBD-like colitis, who 
improved after G-CSF treatment, and reviewed ten cases 
from the literature, ﬁ  ve of which were treated with G-CSF or 
GM-CSF and went on clinical remission of their IBD. Suc-
cessively a series of 36 patients with GSD-1b was described 
(Dieckgraefe et al 2002). In this series, 75% of patients had 
gastrointestinal symptoms, 28% documented IBD and 22% 
had highly suggestive diagnosis of IBD, although diagnos-
tics was not completed. Again, gastrointestinal symptoms 
improved in the patients treated with G-CSF. Similarly, in 
another series 57 cases of GSD-1b (Visser et al 2002), 18 
were treated with G-CSF, showing a reduction in the number 
of infections and an improvement in the severity of their IBD, 
when present. In the nine patients treated for more than one 
year, an increase in neutrophil count was described.
Recent studies have reinforced the hypothesis of an 
innate immune deﬁ  cit in patients with Crohn’s disease: in a 
study concerning acute inﬂ  ammation, Marks and colleagues 
(2006) have shown that in CD patients, trauma to rectum, 
ileum or skin led to abnormally low neutrophil accumulation, 
IL-8 and IL-1β production, as compared to normal subjects 
or other inﬂ  ammatory conditions. Furthermore, Harbord 
and colleagues (2006) have examined the composition 
of exudate in patients with CD and ulcerative colitis 
(UC), and assessed the effect of G-CSF administration 
on tissue penetration of neutrophils in patients. In this 
study, neutrophil and monocyte/macrophage populations 
and inﬂ  ammatory mediators were measured in cantharidin 
blisters at 24 h. Neutrophil chemotaxis was assessed in 
vitro using blister ﬂ  uid as the chemoattractant. Signiﬁ  cantly 
fewer neutrophils migrated into blisters in Crohn’s patients. 
The production of neutrophil chemokines, but not other 
inﬂ  ammatory mediators, was reduced. This correlated with 
reduced chemotaxis in vitro. The administration of two 
subcutaneous injections of G-CSF (5 μg/kg) signiﬁ  cantly 
increased blister neutrophil concentrations in control 
subjects and Crohn’s patients.
Immunodeﬁ  ciency states are by deﬁ  nition associated 
with infections. Immune inadequacy and infections are 
the two sides of the same coin. Recently the interaction 
between IBD and infection has been reviewed (Irwing and 
Gibson 2008), both at the etiopathogenetic level and dur-
ing the clinical course of the disease. These observations 
are the premises to the use of immune-enhancing drugs 
in IBD.
T regulatory cell defect in IBD
The immune system protects a host from pathogens, 
distinguishes self from non-self structures and prevents 
nonessential and self-destructive immune responses through 
mechanisms of central and peripheral tolerance (Danese and 
Rutella 2007). Tolerance can be operationally deﬁ  ned as 
absence of antigen (Ag)-speciﬁ  c pathogenic autoimmunity 
or the acceptance of an allograft, attributable to lack of Ag 
accessibility (ignorance), absence of  T-cells (deletion) or lack 
of sufﬁ  cient activation signals (unresponsiveness). A growing 
body of evidence indicates that speciﬁ  c T-cell populations 
with suppressive/regulatory properties are devoted to the 
maintenance of Ag-speciﬁ  c T-cell tolerance both in mice 
and in humans (Jonuleit and Schmitt 2003). The family of 
regulatory T-cells (Treg) encompasses T-cell populations 
with distinct suppressive mechanisms, eg, naturally occur-
ring CD4+CD25+ Treg cells, T helper type 3 (Th3) cells, and 
Treg type 1 (Tr1) cells. Naturally occurring CD4+CD25+ 
Treg cells develop in the thymus during T-cell maturation 
and survive in the periphery to prevent harmful autoimmune 
reactions. Adaptive Treg cells develop from mature T-cell 
under speciﬁ  c conditions of sub-optimal costimulation or 
Ag exposure. Although earlier studies suggested that these 
might be two distinct subsets, it is currently believed that 
the adaptive Treg cells can either develop from classical 
naive T-cells or differentiate from the naturally occurring 
CD4+CD25+ Treg cells.
In recent years, emphasis has been placed on Treg 
defects in chronic intestinal inﬂ  ammation. Although a state 
of physiological and controlled mucosal inﬂ  ammation exists 
in the normal gut, tolerance to bacterial and dietary Ags is 
an essential feature to maintain intestinal homeostasis. To 
regulate such equilibrium, functionally distinct T-cell subsets 
expressing a regulatory phenotype exist in the intestine and 
down-regulate immune responses.
In a mouse model of IBD obtained by transfer of naïve 
T-cells in immunodeﬁ  cient animals the onset of colitis 
can be prevented by co-transfer of CD4+CD25+ Treg cells 
(Read et al 2000) and these cells can also cure the intestinal Therapeutics and Clinical Risk Management 2008:4(5) 930
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inﬂ  ammation in these mice (Mottet et al 2003). Co-transfer 
of other Treg populations, among which Tr1, can prevent 
intestinal inﬂ  ammation the SCID transfer model (Allez and 
Mayer 2004).
A previously unrecognised role of G-CSF in the in vivo 
generation of human Tr1 cells has been shown (Rutella 
et al 2002; Rutella 2007). These in vitro ﬁ  ndings have been 
backed by in vivo studies demonstrating Tr1-mediated 
protection from graft-versus-host disease in a mouse model 
of G-CSF-mobilized allogeneic stem cell transplantation 
(Morris et al 2004).
Preclinical studies of G-CSF and 
GM-CSF in CD
G-CSF has been used in experimental colitis in white 
New Zealand rabbits, where it reduced leukotriene B4 and 
thromboxane B2 in dialysis ﬂ  uid (Hommes et al 1996). 
Furthermore, in another animal model of IBD (rats treated 
with 2,4,6-trinitrobenzene sulfonic acid) the pretreatment 
with G-CSF attenuated both loss of body weight and 
colonic wall thickening (Egi et al 2003), and this effect was 
associated with a signiﬁ  cant inhibition of IFNγ and IL-12 
p35 transcription.
Sainathan and collegues (2008) examined the effects 
of GM-CSF in the dextran sulfate sodium (DSS)-induced 
acute colitis models. In this study mice were treated with 
daily GM-CSF or phosphate-buffered saline (PBS), during 
colitis induction. The authors have shown that sargramostim 
ameliorates acute DDS-induced colitis, obtaining signiﬁ  -
cant improvement of clinical and histological parameters. 
Furthermore, a reduction has been demonstrated in the 
expression of pro-inﬂ  ammatory genes such TNF-α and IL-1β 
(Sainathan et al 2008).
Clinical studies of GM-CSF in CD
GM-CSF, a myeloid growth factor, plays a pivotal role in 
the development and function of phagocytic cells. GM-
CSF is expressed by CD4+ T-cells and Paneth cells in the 
intestine. Receptors for GM-CSF have been identiﬁ  ed on 
intestinal epithelial cells, including Paneth cells (Fukuzawa 
et al 2003). Moreover, GM-CSF is expressed at high levels 
in those regions of the gastrointestinal tract that are associ-
ated with the greatest concentration of luminal microbial 
colonization. These ﬁ  ndings suggest that GM-CSF may 
help maintain the function of the intestinal innate immune 
barrier and that exogenous GM-CSF may augment host 
defense and ameliorate inﬂ  ammation associated with CD. 
Sargramostim is a recombinant version of the human 
GM-CSF, most commonly used for myeloid-cell recovery 
after chemotherapy.
In an initial pilot study, Dieckgraefe and Korzenick 
(2002) did an 8-week, open label, dose-escalating study of 
GM-CSF for treatment of active Crohn’s disease. Patients 
with a Crohn’s disease activity index (CDAI) score greater 
than 220 and lower than 475 were eligible for enrolment. 
Fifteen patients were screened and all were enrolled. The 
mean starting CDAI was 346 (range 228–471), which indi-
cated a moderate-severe active CD. These patients were not 
receiving concomitant immunosuppressive therapy, whereas 
antibiotics and aminosalicylates were allowed. The primary 
end point was clinical response, deﬁ  ned as a decrease in 
CDAI, at the end of the treatment (day 56), of greater than 
70 points from baseline, and remission, deﬁ  ned as an abso-
lute CDAI of less than 150. Other end points included the 
health-related quality of life, evaluated with inﬂ  ammatory 
bowel-disease questionnaire (IBDQ), and adverse events. 
Patients were enrolled into one of three groups, and were 
given sargramostim at 4, 6, or 8 μg/Kg per day. All patients 
completed 8 weeks of treatment. The daily self-administered 
injections were well tolerated. Twelve of 15 patients reported 
localized reactions at the site of injection, which varied from 
transient itching to a 2–3 cm area of induration and erythema. 
Reactions were generally larger at higher doses and dimin-
ished with continued administration of sargramostim. Ten 
patients had bone pain. A single oral dose of paracetamol 
before subcutaneous GM-CSF injection provided relief for 
most patients. Sargramostim had a dose-dependent effect 
on mean absolute neutrophil counts, which increased to 
13.1, 18.5, and 20 × 109/L by the second week in the 4, 6, 
and 8 μg/kg per day groups, respectively. Mean absolute 
eosinophil counts increased to 4.1, 6.7, and 9.1 × 109/L by 
the second week in the 4, 6, and 8 μg/kg per day groups, 
respectively. Peak effects on absolute neutrophil count and 
absolute eosinophil count tended to take place between 
weeks 2 and 4, with slight decreases by week 8. Changes in 
absolute neutrophil and eosinophil counts were similar in 
the responder and nonresponder groups. After 8 weeks of 
GM-CSF treatment, 12 of 15 patients had a clinical response 
and 8 were in remission. Patients had a progressive weekly 
decrease in CDAI from a pretreatment mean score of 346 to 
156 at week 8. The response rate was 75%, 85% and 75% in 
the 4, 6, and 8 μg/Kg per day dose groups, corresponding to 
a mean decrease in CDAI of 166, 216, and 169, respectively. 
Increased IBDQ score indicates an improved quality of 
life in terms of improved physical, social and emotional 
performance. After 8 weeks the treatment with GM-CSF Therapeutics and Clinical Risk Management 2008:4(5) 931
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was stopped and patients were followed up clinically for 
evidence of increased disease activity. Of the 12 responders, 
one underwent elective surgical resection after cessation of 
treatment, one was offered retreatment at week 11, and two 
were enrolled at week 8 in a maintenance protocol. At week 
12, the remaining 8 responders had a mean CDAI score of 
205, which was signiﬁ  cantly lower than their pretreatment 
baseline score of 358.
In the phase II study, Korzenik and colleagues (2005), 
using a 2:1 ratio, randomly assigned 124 patients with moder-
ate to severe active CD to receive 6 μg/Kg of sargramostim 
per day or placebo subcutaneously for 56 days. Patients who 
had been taking stable doses of antibiotics or aminosalicylites 
for at least four weeks were eligible. Patients who had been 
taking azathioprine, mercaptopurine, methotrexate, or oral 
or rectal glucocorticoids within 4 weeks before the study 
began were not eligible, nor were those who had been receiv-
ing anti-TNF-α therapy within 12 weeks before the study 
began. Moreover, prior use of sargramostim or ﬁ  lgrastim 
(rhuG-CSF) was prohibited. Efﬁ  cacy measures included 
changes from base line in disease severity (measured by 
CDAI score), mucosal healing (measured using the Crohn’s 
Disease Endoscopic Index of Severity), and health-related 
quality of life (measured by IBDQ score), while safety was 
assessed according to the incidence of adverse events.
The primary end point was a clinical response deﬁ  ned by 
a decrease from baseline of at least 70 points in the CDAI 
score at the end of treatment (day 57). Prospectively deﬁ  ned 
secondary end points included a clinical response deﬁ  ned 
by a decrease of at least 100 points in the CDAI score, 
remission (deﬁ  ned by a CDAI score of 150 or less), and an 
increase in the IBDQ score. Of the 124 treated patients, 81 
received sargramostim and 43 placebo. All demographic and 
disease characteristics, including prior use of therapy for 
CD, were similar in the two groups except for the median 
age and the duration of disease, which were younger and 
shorter, respectively, in the sargramostim group than in the 
placebo group. Ninety percent of patients had previously 
received glucocorticoids, and 69% had received immu-
nosuppressive agents. There was no signiﬁ  cant difference 
between groups in the rate of the primary end point of 
clinical response (54% in sargramostim group as compared 
with 44% in the placebo group; P = 0.28). However, there 
were positive secondary outcomes with regard to the end 
points of a decrease from baseline at least 100 points in the 
CDAI score and remission (48% in sargramostim group 
vs 26% in the placebo group, P = 0.01, and 40% vs. 19%, 
P = 0.01). Moreover, the time to response was signiﬁ  cantly 
shorter in the sargramostim-treated group (P = 0.018), and 
the signiﬁ  cant between-group differences in response and 
remission were maintained at the 30-day post-treatment 
follow-up visit. Sargramostim therapy was also associated 
with improvements in mucosal healing and particularly, in 
quality of life, and the same was for the improvements in the 
health-related quality of life. There was no signiﬁ  cant differ-
ence in the overall incidence of adverse events between the 
sargramostim group and the placebo group (98% vs. 93%, 
P = 0.22). Two types of adverse advents were reported more 
frequently in the sargramostim group than in placebo group: 
injection-site reactions and bone pain.
Clinical studies of G-CSF in CD
A case report by Vaughan and Drumm (1999) described 
the successful treatment of ﬁ  stulas with G-CSF in a CD 
patients.
Successively, recombinant human G-CSF (rhuG-CSF) 
has been administered to ﬁ  ve patients with CD and severe 
endoscopic postoperative recurrence (Dejaco et al 2003). 
They received 300 μg rhuG-CSF subcutaneously three 
times weekly for 12 weeks. It was safe and well tolerated. 
All patients achieved clinical remission, while two of 
them showed also complete mucosal healing. Neutrophil 
counts, IL-1 receptor antagonist and soluble TNF receptors 
p55 and p75 plasma levels were increased during drug 
administration.
Korzenik and Dieckgraefe (2005) have evaluated the use 
of ﬁ  lgrastim (rhuG-CSF) with an open-labeled, 12 week trial 
for the treatment of active CD. In this study, twenty patients 
with active luminal CD and CDAI  220 and  450 were 
enrolled (three had perianal ﬁ  stulas as well, one had entero-
cutaneous ﬁ  stulas). Concomitant immunosuppressant were 
prohibited, whereas mesalazine compounds and antibiotics 
were permitted if used for at least 8 weeks and at stable dose 
for 4 weeks. Steroids were permitted if on for at least 8 weeks 
and with a stable dose of prednisone of  20 mg/day for at 
least 4 weeks. The primary end-point was a decrease in the 
CDAI of  70 points, whereas remission was considered to 
be a CDAI  150. The mean CDAI at initiation was 307 ± 
54. All patients received rhuG-CSF daily for 12 weeks at an 
initial dose of 300 μg self-administered subcutaneously. The 
absolute neutrophil count (ANC) was targeted between 25 
and 35 × 109/L and the dose was adjusted if patients’ ANC 
exceeded this range. Dose reduction because of a greater 
than the target range was necessary in all but three patients. 
However, responders and non responders did not differ sig-
niﬁ  cantly with regard to their μg/Kg dose. Thirteen patients Therapeutics and Clinical Risk Management 2008:4(5) 932
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completed the 12 weeks of the study; seven patients withdrew, 
three for worsening disease, one for an intercurrent illness, 
one because needed surgery, one discontinued due to a lack 
of improvement, and one due to a small perianal abscess at 
the site of a ﬁ  stula. The mean CDAI at week 4 was 229 ± 98 
which represent a statistically signiﬁ  cant change compared 
with week 0. The mean CDAI for those completing the 
12-week study was 162 ± 82. Eleven patients had a decrease 
of at least 70 points and eight decreased more than 100 
points. Five patients were in remission. Patients were seen in 
follow-up 4 weeks after completion of therapy. Among the 
11 responders at week 12, four maintained a response lasting 
for additional 4 weeks while the others had an increase in 
disease activity although still below baseline (mean CDAI 
81 ± 64 below week 0). A response, deﬁ  ned as closure of 
more than 50% of ﬁ  stulae, was demonstrated in three of four 
patients with ﬁ  stulous disease. Adverse events were limited 
and transient. Most patients experienced bone pain that was 
minimized by a single oral dose of acetaminophen admin-
istered before injections. However, all bone pain resolved 
within a few weeks and with continued rhuG-CSF therapy. 
Interpretation of the results of this study is complicated by 
the issue of dosing. Ten patients had a reduction of the dose 
during the study. However, the dose of most individuals was 
decreased early on and the duration and extent of beneﬁ  t may 
have been limited by the dose administered.
Discussion and conclusions
Improvement in gastrointestinal symptoms has been 
noted in patients with immunodeﬁ  ciency diseases when 
treated with G-CSF and GM-CSF (Yamaguchi et al 2001; 
Dieckgraefe et al 2002; Visser et al 2002).
The results of clinical trials conducted in CD are 
summarized in Table 1.
GM-CSF (Dieckgraefe and Korzenik 2002) has been sug-
gested to be beneﬁ  cial in an open-labeled pilot trial in CD.
The randomized, placebo-controlled trial with sargramos-
tim (GM-CSF) was negative as designed (Korzenik et al 
2005) with no signiﬁ  cant difference between groups in the 
rate of the primary end point of a clinical response deﬁ  ned 
by a decrease from baseline of at least 70 points in the CDAI 
score on day 57 (54% in sargramostim group, as compared 
with 44% in the placebo group; P = 0.28). These results might 
have been affected by the high rate of response in the placebo 
group. However, there were positive secondary outcomes 
with regard to the end points of a decrease from baseline of 
at least 100 points in the CDAI score and remission on day 57 
as well as a decrease of at least 70 points in the CDAI score 
at other times. Clinical responses were achieved without 
concomitant immunosuppressive therapy, were rapid and sus-
tained, and were associated with signiﬁ  cant improvements in 
disease speciﬁ  c quality of life. Improvements were observed 
in mucosal healing in sargramostim-treated group.
For what concerns G-CSF the open-label trials have 
shown efﬁ  cacy: 5/5 remissions and 2/5 mucosal healing in 
the small study on postoperative recurrence (Dejaco et al 
2003); in the successive study on active CD (Korzenik 
and Dieckgraefe 2005), of the thirteen patients which have 
completed the study, eleven achieved the primary end points 
(decrease in the CDAI of at least 70 points from baseline) 
and ﬁ  ve were in remission.
Both drugs were safe in these reports, showing more 
frequently minor adverse events related to the injection 
site and transient bone pain. However, dose reduction was 
necessary for most patients treated with G-CSF (Korzenik 
and Dieckgraefe 2005), because of excessive ANC.
Experimental and clinical studies have shown differences 
between ﬁ  lgrastim and sargramostim. The available data 
have suggested that GM-CSF is associated with a more 
wide and potent action on multiple cells, such as neutrophils, 
monocytes, and intestinal epithelial cells which expressed 
receptors for GM-CSF. On the other hand G-CSF has a 
more selective effect on the innate immune system, acting on 
neutrophils, but its action could be exerted by a modulation 
of T regulatory cell.
Further studies are warranted, both to establish the real 
efﬁ  cacy of these drugs and to elucidate the modiﬁ  cations 
produced in the immune system of IBD patients by the 
treatment.
Points that need to be addressed by future research include 
the evaluation of the response to the treatment of patients 
with early onset of the disease, given the initial role of the 
innate immunity and of T regulatory cells in the models of 
immunopathogenesis of CD. Furthermore, these drugs could 
be useful for those patients having neutropenia, mainly as a 
consequence of treatments with azathioprine or other immu-
nosuppressant drugs, and for those with infections and septic 
complications, which are particularly common in ﬁ  stulizing 
CD. Finally, as these drugs can be considered as immune 
enhancer rather than suppressors, a theoretical possibility of 
combination with anti-TNF or other biologicals exists, and 
could be explored in animal models.
In conclusion, the results of the reported studies suggest 
that a treatment designed to modulate intestinal mucosa 
immune homeostasis (including innate immunity and the 
T regulatory network) with colony-stimulating factors such Therapeutics and Clinical Risk Management 2008:4(5) 933
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as G-CSF and GM-CSF might have a role in patients with 
Crohn’s disease.
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